Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

260
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
260
Hepatic Portal System01:21

Hepatic Portal System

5.5K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.5K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

219
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
219
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

539
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
539
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

304
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
304
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.7K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab-Induced Serum Sickness in a Seven-Year-Old Child With Nephrotic Syndrome.

Cureus·2025
Same author

[Failure predictors with oxygen therapy by high-flow nasal catheter in children under 2 years of age with acute lower respiratory infections].

Andes pediatrica : revista Chilena de pediatria·2025
Same author

Prophylaxis with emicizumab in children under 12 years old with haemophilia A without inhibitors in Uruguay: National experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2024
Same author

Fibrodysplasia ossificans progressiva in a 3-year-old female patient.

Boletin medico del Hospital Infantil de Mexico·2023
Same author

[Intestinal parasites in schoolchildren, public health problem. Intervention from the National Integrated Health System of Uruguay].

Revista de salud publica (Bogota, Colombia)·2023
Same author

[Epidemiological and clinical characteristics of children with COVID-19 cared for in a private health provider in Uruguay].

Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia·2022

Related Experiment Video

Updated: Jan 21, 2026

Multifocal Electroretinograms
16:49

Multifocal Electroretinograms

Published on: December 4, 2011

18.8K

[Multifocal hepatic hemangioendothelioma].

Carlos Zunino1, Maira Delgado2, Gustavo Giachetto1

  • 1Departamento de Pediatría, Facultad de Medicina, Universidad de la República, Uruguay.

Revista Chilena De Pediatria
|July 26, 2019
PubMed
Summary

Multifocal hepatic hemangioendothelioma, a rare childhood tumor, was diagnosed in an infant using imaging. High-dose corticosteroid treatment led to tumor remission but caused side effects.

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.5K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.9K

Related Experiment Videos

Last Updated: Jan 21, 2026

Multifocal Electroretinograms
16:49

Multifocal Electroretinograms

Published on: December 4, 2011

18.8K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.5K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.9K

Area of Science:

  • Pediatric Oncology
  • Hepatology
  • Medical Imaging

Background:

  • Hepatic hemangioendothelioma is a rare, benign pediatric liver tumor, often presenting in infancy with varied clinical signs.
  • Diagnosis relies on clinical suspicion, laboratory tests, and advanced imaging modalities.
  • Multifocal hepatic hemangioendothelioma requires careful diagnostic consideration due to its rarity and potential complications.

Observation:

  • A 3-month-old female infant presented with hepatomegaly, lacking signs of hepatic or heart failure.
  • Abdominal ultrasound, CT scan, and CT angiography confirmed multifocal hepatic hemangioendothelioma.
  • The patient underwent prolonged, high-dose glucocorticoid therapy.

Findings:

  • The treatment resulted in tumor remission within 1.5 years.
  • The patient experienced adverse effects secondary to the prolonged corticosteroid treatment.
  • Despite side effects, the tumor's extent and potential complications justified the therapeutic approach.

Implications:

  • Hepatomegaly in asymptomatic infants warrants investigation for potential tumor pathology, integrating clinical and imaging data.
  • Risk-benefit assessment of treatment, including potential complications and adverse effects, is crucial.
  • Prolonged, high-dose corticosteroid therapy can be effective for extensive hepatic hemangioendothelioma, necessitating vigilant monitoring for side effects.